DE602006014949D1 - Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs - Google Patents

Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs

Info

Publication number
DE602006014949D1
DE602006014949D1 DE602006014949T DE602006014949T DE602006014949D1 DE 602006014949 D1 DE602006014949 D1 DE 602006014949D1 DE 602006014949 T DE602006014949 T DE 602006014949T DE 602006014949 T DE602006014949 T DE 602006014949T DE 602006014949 D1 DE602006014949 D1 DE 602006014949D1
Authority
DE
Germany
Prior art keywords
cancer
treatment
nucleoside compounds
phosphoramidate derivatives
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006014949T
Other languages
English (en)
Inventor
Christopher Mcguigan
Kenneth Mills
Costantino Congiatu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardiff Protides Ltd
Original Assignee
Cardiff Protides Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiff Protides Ltd filed Critical Cardiff Protides Ltd
Publication of DE602006014949D1 publication Critical patent/DE602006014949D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE602006014949T 2005-03-21 2006-03-16 Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs Active DE602006014949D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0505781.5A GB0505781D0 (en) 2005-03-21 2005-03-21 Chemical compounds
PCT/GB2006/000932 WO2006100439A1 (en) 2005-03-21 2006-03-16 Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
DE602006014949D1 true DE602006014949D1 (de) 2010-07-29

Family

ID=34531603

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006014949T Active DE602006014949D1 (de) 2005-03-21 2006-03-16 Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs

Country Status (20)

Country Link
US (1) US8263575B2 (de)
EP (1) EP1866324B1 (de)
JP (2) JP5345381B2 (de)
CN (2) CN101175763A (de)
AT (1) ATE471334T1 (de)
AU (1) AU2006226182C1 (de)
BR (1) BRPI0609704B8 (de)
CA (1) CA2602324C (de)
CY (1) CY1111538T1 (de)
DE (1) DE602006014949D1 (de)
DK (1) DK1866324T3 (de)
ES (1) ES2348741T3 (de)
GB (1) GB0505781D0 (de)
IL (1) IL186104A (de)
MX (1) MX2007011666A (de)
PL (1) PL1866324T3 (de)
PT (1) PT1866324E (de)
SI (1) SI1866324T1 (de)
WO (1) WO2006100439A1 (de)
ZA (1) ZA200709011B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0623493D0 (en) * 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
AU2012216500B2 (en) * 2006-11-24 2013-06-20 Katholieke Universiteit Leuven Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
TW201026715A (en) 2008-12-23 2010-07-16 Pharmasset Inc Nucleoside phosphoramidates
MX2011006890A (es) 2008-12-23 2011-07-20 Pharmasset Inc Analogos de nucleosidos.
JP5793084B2 (ja) 2008-12-23 2015-10-14 ギリアド ファーマセット エルエルシー プリンヌクレオシドの合成
JP2012514657A (ja) 2009-01-09 2012-06-28 ユニバーシテイ・カレツジ・オブ・カーデイフ・コンサルタンツ・リミテツド ウィルス感染を治療するためのグアノシンヌクレオシド化合物のホスホルアミダート誘導体
PT2552930E (pt) 2010-03-31 2015-11-17 Gilead Pharmasset Llc 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin- 1-(2h)-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2- il)metoxi) (fenoxi)fosforil)amino)propanoato de (s)- isopropilo cristalino
GB201016855D0 (en) * 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
EP2658857B1 (de) 2010-12-29 2016-11-02 Inhibitex, Inc. Substituierte purin-nukleoside, phosphoroamidate und phosphorodiamidatderivate zur behandlung von virusinfektionen
US9095599B2 (en) 2011-01-03 2015-08-04 Nanjing Molecular Research, Inc. O-(substituted benzyl) phosphoramidate compounds and therapeutic use
HRP20211967T1 (hr) 2011-03-01 2022-03-18 NuCana plc Farmaceutska formulacija koja sadrži fosforamidatni derivat 5-fluoro-2'-deoksiuridina za uporabu u liječenju raka
WO2012125900A1 (en) 2011-03-16 2012-09-20 Enanta Pharmaceuticals, Inc. 2'-allene-substituted nucleoside derivatives
CN104903339A (zh) 2012-11-16 2015-09-09 卡迪夫大学学院顾问有限公司 用于制备核苷前体药物的方法
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
CA2931458A1 (en) * 2013-11-27 2015-06-04 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer
CN106459127A (zh) * 2014-05-28 2017-02-22 艾登尼克斯药业有限公司 用于治疗癌症的核苷衍生物
KR20170005492A (ko) * 2014-05-28 2017-01-13 아이데닉스 파마슈티칼스 엘엘씨 암의 치료를 위한 뉴클레오시드 유도체
EP3683225A1 (de) 2014-11-28 2020-07-22 Nucana PLC Neue 2'- und/oder 5'-aminosäureesterphosphoramidat 3'-deoxyadenosinderivate als antikrebsverbindungen
CN107427530B (zh) 2015-03-06 2020-09-08 阿堤亚制药公司 用于HCV治疗的β-D-2’-脱氧-2’α-氟-2’-β-C-取代的-2-改性的-N6-取代的嘌呤核苷酸
US10745435B2 (en) 2015-11-16 2020-08-18 Cerecor, Inc. Nucleic acid prodrugs
GB201522764D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609602D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
GB201609601D0 (en) * 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
JP2019526596A (ja) 2016-09-07 2019-09-19 アテア ファーマシューティカルズ， インコーポレイテッド Ｒｎａウイルス治療に対する２’−置換−ｎ６−置換プリンヌクレオチド
WO2018071675A1 (en) * 2016-10-12 2018-04-19 Georgetown University Cd99 inhibitors and their uses
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
GB201904544D0 (en) 2019-04-01 2019-05-15 NuCana plc Anticancer compounds
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CN113549076B (zh) * 2021-07-23 2022-12-06 中国药科大学 一种多取代嘌呤类化合物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880000094B1 (ko) 1984-12-07 1988-02-23 보령제약 주식회사 뉴클레오시드 유도체의 제조방법
CA2004695C (en) 1988-12-12 1999-08-10 Rosanne Bonjouklian Phospholipid nucleosides
DE4418690A1 (de) * 1994-05-28 1996-01-11 Boehringer Mannheim Gmbh Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
EP0821692B1 (de) 1995-04-21 2006-01-11 University Of South Florida Immunopotenzierende 5'-nucleotidase-resistente inosinmonophosphat-derivate und ihre verwendung
JP3761958B2 (ja) 1996-03-12 2006-03-29 彰 松田 ３′−カルバモイルアルキルヌクレオシド誘導体
WO1999037753A1 (en) * 1998-01-23 1999-07-29 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
GB9821058D0 (en) * 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
JP4768909B2 (ja) 2000-09-29 2011-09-07 扶桑薬品工業株式会社 トポイソメラーゼ阻害剤
US20030073618A1 (en) * 2001-02-08 2003-04-17 Kozhemyakin Leonid A. Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof
DE10108851A1 (de) * 2001-02-23 2002-09-12 Resprotect Gmbh Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten
AU2002322325A1 (en) * 2001-06-22 2003-01-08 Emory University Beta-2'-or 3'-halonucleosides
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
EP1773355B1 (de) * 2004-06-24 2014-06-25 Merck Sharp & Dohme Corp. Nukleosid-aryl-phosporamidate zur behandlung von rna-abhängiger rna-viralinfektion
CA2618335C (en) * 2005-08-15 2015-03-31 F.Hoffmann-La Roche Ag Antiviral phosphoramidates of 4'-substituted pronucleotides

Also Published As

Publication number Publication date
AU2006226182A1 (en) 2006-09-28
JP2013173786A (ja) 2013-09-05
IL186104A0 (en) 2008-01-20
PL1866324T3 (pl) 2010-12-31
CN103936807A (zh) 2014-07-23
SI1866324T1 (sl) 2010-10-29
EP1866324A1 (de) 2007-12-19
ZA200709011B (en) 2009-01-28
US8263575B2 (en) 2012-09-11
CA2602324C (en) 2015-02-24
US20090215715A1 (en) 2009-08-27
AU2006226182B2 (en) 2011-09-01
GB0505781D0 (en) 2005-04-27
WO2006100439A1 (en) 2006-09-28
EP1866324B1 (de) 2010-06-16
BRPI0609704B8 (pt) 2021-09-28
BRPI0609704B1 (pt) 2020-12-01
JP2008533191A (ja) 2008-08-21
DK1866324T3 (da) 2010-09-27
JP5345381B2 (ja) 2013-11-20
CY1111538T1 (el) 2015-08-05
JP5863702B2 (ja) 2016-02-17
AU2006226182C1 (en) 2012-06-14
ES2348741T3 (es) 2010-12-13
PT1866324E (pt) 2010-09-16
MX2007011666A (es) 2007-11-14
BRPI0609704A2 (pt) 2010-04-20
ATE471334T1 (de) 2010-07-15
CA2602324A1 (en) 2006-09-28
IL186104A (en) 2013-06-27
CN101175763A (zh) 2008-05-07

Similar Documents

Publication Publication Date Title
ATE471334T1 (de) Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs
NL301145I2 (nl) Tirbanibulin
CY1122973T1 (el) Συνθεση υγρου διαπιδυσης η οποια περιλαμβανει ουσιες αναστολης της κρυσταλλωσης
DE602004015811D1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
TW200716141A (en) Compositions and methods for treatment for neoplasms
EA201100158A1 (ru) Антагонисты активина-actriia и их применение для стимулирования роста кости
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
CY1126007T1 (el) Προαγωγεις αποπτωσης
BRPI0513310A (pt) análogos de tetrapeptìdeo
TW200801008A (en) Protein kinase inhibitors
ATE554114T1 (de) Copolymer mit zwitterionischen einheiten und anderen einheiten, das copolymer umfassende zusammensetzung und verwendung
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
DE502006005290D1 (de) Niedrigviskose uretdiongruppenhaltige polyadditionsverbindungen, verfahren zur herstellung und verwendung
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
MX2008001538A (es) Aril piridinas y metodos para su uso.
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE397000T1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
NO20082425L (no) Formuleringer omfattende jorumycin-, reni-eramycin-, safracin- eller saframycin-relaterte forbindelser for behandling av proliferative sykdommer
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis
MX2010005324A (es) Composiciones y metodos para inhibir el avance del tumor.
DE602005015329D1 (de) Rutheniumkomplexe zur krebsbehandlung